Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 3/20 | 0.34 |
| ▸ | BRD9 | Q9H8M2 | 3/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.34 |
| ▸ | BPTF | Q12830 | 2/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGAV | P06756 | 1/20 | 0.34 |
| ▸ | FLT1 | P17948 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3111828 | 0.90 | NTRK1 (0.36) | NTRK1LPAR1BRD4BRD9KAT2B | |
| SCHEMBL6425423 | 0.90 | HPGD (0.40) | MAPK1NTRK1GAA | |
| SCHEMBL6065837 | 0.88 | LPAR1 (0.37) | NTRK1LPAR1BRD4BRD9KAT2B | |
| SCHEMBL5497720 | 0.88 | KDM4E (0.36) | RECQLMAPK1NTRK1LPAR1BRD4 | |
| Carbamic Acid SCHEMBL5499998 | 0.87 | CA1 (0.40) | RECQLCA1CA2NTRK1LPAR1 | |
| SCHEMBL3119092 | 0.87 | LPAR1 (0.38) | NTRK1LPAR1BRD4BRD9KAT2B | |
| SCHEMBL27620832 | 0.86 | CETP (0.44) | MAPK1GAA | |
| SCHEMBL6425412 | 0.86 | ALDH1A1 (0.37) | NTRK1LPAR1BRD4BRD9KAT2B | |
| SCHEMBL5494715 | 0.85 | ITGB3 (0.36) | NTRK1BRD4BRD9ITGB3ITGAV | |
| SCHEMBL6427861 | 0.85 | NTRK1 (0.35) | NTRK1LPAR1BRD4BRD9KAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556389-B9 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-09-09 | — | — | EP | disclosed |
| EP-1556389-B3 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-04-01 | — | — | EP | disclosed |
| CN-100343260-C | Cephem compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 2007-10-17 | — | — | CN | disclosed |
| EP-1556389-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2007-07-25 | — | — | EP | disclosed |
| US-20070037786-A1 | Cephem compounds | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-7129232-B2 | For therapy of of infectious diseases | ASTELLAS PHARMA INC. (JP) | 2006-10-31 | — | — | US | disclosed |
| CN-1708502-A | Cephem compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-12-14 | — | — | CN | disclosed |
| EP-1556389-A1 | CEPHEM COMPOUNDS | Astellas Pharma Inc. (JP) | 2005-07-27 | — | — | EP | disclosed |
| US-20040132994-A1 | Cephem compounds | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-07-08 | — | — | US | disclosed |
| WO-2004039814-A1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037786-A1 | Cephem compounds | CEP170, ABCB11, SLC7A1 | ADRA2C 501/4885CYP1A2 315/4885CYP3A4 477/4885 |
| US-20040132994-A1 | Cephem compounds | CEP170, ABCB11, RCC2 | ADRA2C 512/4885CYP1A2 443/4885CYP3A4 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.